News

The McSwiggen patent estate broadly describes chemical modifications of RNAi therapeutics needed to achieve "drug-like" properties in siRNA, the molecules that mediate RNAi. Specifically, the ‘277 patent includes

On May 1, 2014 Parion announced FDA Acceptance of the Investigational New Drug Application for clinical testing of P-321 Ophthalmic Solution for the Treatment of Dry Eye Disease.

DiaPep277 is currently being evaluated in a fully enrolled confirmatory Phase 3 clinical study in adult patients, with results anticipated in the first quarter of 2015. DiaPep277 holds

Under the deal, AstraZeneca will pay Synairgen a $7.25m up-front fee and potential development, regulatory and commercial milestones of about $225m. Additionally, AstraZeneca will pay tiered royalties ranging

Prasco has product inventory available and has started shipping product. Testim and its authorized generic version are testosterone gels approved by the US Food and Drug Administration (FDA)

The company said that ACT creates a new funding model to speed research for its potential use by pediatric patients. Seattle Children’s Research Institute president Jim Hendricks said

ErepoXen is an improved, polysialylated form of erythropoietin (EPO), a hormone produced by the kidneys for maintaining the production of red blood cells and prevent anemia. The drug

The iCAPS platform can isolate and present functional GPCRs in their correct confirmation to identify selective monoclonal antibody inhibitors or activators with great specificity for more effective therapeutics.

The company is dedicated to identifying, in-licensing and developing promising therapeutic candidates. The patent, when issued, will be valid until at least 2026, while additional patents claiming the